Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"

   Hotel Registration
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Wissenschaftliches Programm
   Scientific program
   Poster Presentation
Begleitende Veranstaltungen
   Accompanying program
   Working sessions
   Social program
Allgemeine Informationen
   General Information
   Index of Authors
   Commercial exhibitors

DOG Homepage


Posterior Juxtascleral Delivery of Anecortave Acetate for the Treatment of Choroidal Neovascularization – Long-term Outcomes and Current Status

Schmidt-Erfurth U., Michels S., Michels R, Robertson S., Michaud J.-E., and the Anecortave Acetate Clinical Study Group
University Hospital Schleswig-Holstein, Campus Luebeck

Purpose: To evaluate the clinical efficacy of angiostatic anecortave acetate administered as a posterior juxtascleral depot in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD)
Method: 128 patients were treated at 18 sites world-wide in the ongoing prospective dose-response study over 24 months of follow-up. Patients were randomized to either anecortave acetate at dosages of 3, 15 or 30 mg or placebo treatment. Patients were re-treated at 6-month intervals, if the patient could benefit in the investigator’s opinion. Clinical safety has been monitored with periodic physical and detailed ophthalmic examinations. Clinical efficacy is being assessed by evaluations of logMAR visual acuity based on ETDRS criteria and angiographic lesion characteristics over time.
Results: An evaluation of the Month 12 data in late 2002 showed that anecortave acetate at a dose of 15mg was statistically superior to placebo. This advantage was found in respect to prevention of both moderate vision loss (79% vs. 53%, p = 0.0323) and severe vision loss (3% vs. 23%, p = 0.0224). There was also a trend favoring anecortave acetate (15mg) for inhibition of CNV growth. No clinically relevant drug-related or administration-r

Zurück | Back